Abstract
Variations in drug uptake and efflux, as well as changes in intracellular drug entrapment and distribution may represent important resistance mechanisms to cancer therapy. A variety of ATP binding cassette transporters (ABC) localised in multiple cell membranes is implied in those phenomena, representing a mechanism of protection of cells against xenobiotics. Many cancer cell lines over express some ABC transporters, especially p-glycoprotein, MRP1 and BCRP. This over expression is related to worse cancer treatment outcome and, in some cases, reduced overall survival of cancer patients. This paper reviews the location and physiological role of the three transporters mentioned and also describes the drugs that are substrates of these proteins. The usefulness of animal and cellular models to evaluate the role of these transporters on the uptake and efflux of anticancer drugs is discussed. Finally, the results of preclinical and clinical studies about the utility of some inhibitors of these pumps, as well as the implications of polymorphism of ABC transporters on the efficacy and safety of anticancer therapeutics are reported.
Keywords: abc (atp binding cassette) transporters, abcg2 transporter (atp-binding cassette transporter placentaspecific, abcp, breast cancer resistance protein, bcrp, and mitoxantrone-resistance protein, mrx), anticancer therapeutics, multidrug resistance (mdr), modulation of mdr
Current Drug Delivery
Title: Relevance of Multidrug Resistance Proteins on the Clinical Efficacy of Cancer Therapy
Volume: 1 Issue: 3
Author(s): V. Merino, N. V. Jiménez-Torres and M. Merino-Sanjuan
Affiliation:
Keywords: abc (atp binding cassette) transporters, abcg2 transporter (atp-binding cassette transporter placentaspecific, abcp, breast cancer resistance protein, bcrp, and mitoxantrone-resistance protein, mrx), anticancer therapeutics, multidrug resistance (mdr), modulation of mdr
Abstract: Variations in drug uptake and efflux, as well as changes in intracellular drug entrapment and distribution may represent important resistance mechanisms to cancer therapy. A variety of ATP binding cassette transporters (ABC) localised in multiple cell membranes is implied in those phenomena, representing a mechanism of protection of cells against xenobiotics. Many cancer cell lines over express some ABC transporters, especially p-glycoprotein, MRP1 and BCRP. This over expression is related to worse cancer treatment outcome and, in some cases, reduced overall survival of cancer patients. This paper reviews the location and physiological role of the three transporters mentioned and also describes the drugs that are substrates of these proteins. The usefulness of animal and cellular models to evaluate the role of these transporters on the uptake and efflux of anticancer drugs is discussed. Finally, the results of preclinical and clinical studies about the utility of some inhibitors of these pumps, as well as the implications of polymorphism of ABC transporters on the efficacy and safety of anticancer therapeutics are reported.
Export Options
About this article
Cite this article as:
Merino V., Jiménez-Torres V. N. and Merino-Sanjuan M., Relevance of Multidrug Resistance Proteins on the Clinical Efficacy of Cancer Therapy, Current Drug Delivery 2004; 1 (3) . https://dx.doi.org/10.2174/1567201043334650
DOI https://dx.doi.org/10.2174/1567201043334650 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy
Current Cancer Drug Targets Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics Systematic Patent Review of Nanoparticles in Drug Delivery and Cancer Therapy in the Last Decade
Recent Advances in Drug Delivery and Formulation Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Current Stem Cell Research & Therapy Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets Status of Anti-Lung Cancer Drug Patents Applications in China from 2003 to 2012
Recent Patents on Anti-Cancer Drug Discovery The Interest of Folic Acid in Targeted Photodynamic Therapy
Current Medicinal Chemistry Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Current Cancer Drug Targets Herpes Simplex Virus Vectors for the Nervous System
Current Gene Therapy Thyroid Ultrasound and Other Imaging Procedures in the Pediatric Age
Current Pediatric Reviews Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance
Current Protein & Peptide Science Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets Synthesis and In Vitro Study of the Anticancer Activity of New Analogs of Octreotide
Protein & Peptide Letters Cucurbitacins as Inducers of Cell Death and a Rich Source of Potential Anticancer Compounds
Current Pharmaceutical Design Smart Stimuli Sensitive Nanogels in Cancer Drug Delivery and Imaging: A Review
Current Pharmaceutical Design Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Calcium-suppressed Technique in Dual-layer Detector Computed Tomography to Evaluate Knee Articular Cartilage
Current Medical Imaging iNOS: A Potential Therapeutic Target for Malignant Glioma
Current Molecular Medicine Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs
Mini-Reviews in Medicinal Chemistry